Fiji vs Switzerland: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Fiji
92.0%
in 2025
Switzerland
92.0%
in 2025
Fiji rank
54th
Switzerland rank
54th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Fiji
- Switzerland
How they compare
Fiji currently reports 92.0% against 92.0% in Switzerland, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Switzerland ahead.
Fiji ranks 54th and Switzerland ranks 54th of 192 countries.
Across the 3 decades both report, Fiji averaged higher in 1 and Switzerland in 2.
Head to head by decade
| Decade | Fiji | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 19.0% | 19.0% | Switzerland |
| 2010s | 65.8% | 71.6% | 5.8% | Switzerland |
| 2020s | 95.0% | 89.2% | 5.8% | Fiji |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Fiji or Switzerland?
- Fiji, at 92.0% against 92.0% in Switzerland as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Fiji and Switzerland?
- 0.0%, with Fiji ahead.
- How many years of comparable data are there for Fiji and Switzerland?
- 18 years are reported by both, from 2008 to 2025.
- How do Fiji and Switzerland rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Fiji ranks 54th and Switzerland ranks 54th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.